News
New research highlights significant insurance-driven hurdles, increasing second-line uptake of Fabhalta (Novartis), and strong physician interest in pipeline therapies including zaltenibart (Omeros), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results